245
Participants
Start Date
August 8, 2022
Primary Completion Date
October 12, 2023
Study Completion Date
December 13, 2023
Semaglutide
Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Placebo
Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Szent Margit Rendelőintézet Nonprofit Kft., Budapest
ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft., Budapest
Bajcsy-Zsilinszky Kórház, Budapest
MH Egészségügyi Központ, Budapest
Selye János Kórház és Rendelőintézet, Komárom
Northport VA Med Ctr Northport, Northport
Albany Medical College - Endo, Albany
Mid Hudson Med Res-New Windsor, New Windsor
Southgate Medical Group, LLP, West Seneca
Clinical Research of Philadelphia, Philadelphia
MD Medical Research, Oxon Hill
MedStar Community Clin Res Ctr, Hyattsville
Endo And Metab Cons, Rockville
UNC Eastowne Clinical Research Unit, Chapel Hill
Accellacare, Wilmington
Northeast Res Inst. Inc., Jacksonville
Clinical Neuroscience Solution, Orlando
San Marcus Res Clin Miami Lakes, Miami Lakes
Univ of Alabama Birmingham, Birmingham
University of Alabama Birmingham, Birmingham
Holston Medical Group, Kingsport
Clinical Neuroscience Solutions, Memphis
The Research Group of Lexington LLC, Lexington
Advanced Med Res Maumee, Maumee
Providence Health Partners Ctr, Dayton
Arcturus Healthcare, PLC, Troy
West Broadway Clinic, Council Bluffs
Clinical Inv Spec, Inc.Kenosha, Kenosha
Lillestol Research LLC, Fargo
Cedar-Crosse Research Center, Chicago
StudyMetrix Research LLC, City of Saint Peters
Cotton O'Neil Clin Research Ctr, Topeka
Velocity Clinical Res-Dallas, Dallas
Consano Clinical Research, LLC, Shavano Park
Amarillo Med Spec LLP, Amarillo
Solaris Clinical Research, Meridian
Velocity Clin Res Wstlke, Los Angeles
Velocity Clin Res Gardena, Gardena
National Research Institute_Huntington Park, Huntington Park
San Diego Family Care_San Diego, San Diego
Southern California Res Ctr, Coronado
Velocity Clinical Res-Banning, Banning
First Valley Med Grp Lancaster, Lancaster
Mills-Peninsula Hlth Services, San Mateo
Diablo Clinical Research, Inc., Walnut Creek
Velocity Clinical Res Medford, Medford
Velocity Clin Res Grants Pass, Grants Pass
Brigham & Women's Hospital, Boston
Premier Research Inc., Trenton
UT Southwestern Med Cntr, Dallas
University Hospital of Athens ATTIKON, Haidari-Athens
Iatriko Psychicou Private Clinic, Athens
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter, Athens
Alexandra General Hospital, Therapeutic Clinic, Athens
Iatriko Athinon (Athens Medical Canter), Athens
Iatriko Athinon 'Palaiou Falirou', Athens
'Ippokrateio' General Hospital of Thessaloniki, Thessaloniki
General Hospital of Thessaloniki 'G. Gennimatas, Thessaloniki
EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes, Thessaloniki
"Thermi Private Hosital", Thessaloniki
"General Hospital of Thessaloniki G.Papanikolaou", Thessaloniki
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ, Szeged
Markusovszky Egyetemi Oktatókórház, Szombathely
NBR Polska, Warsaw
NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska, Bialystok
NZOZ Vita-Diabetica Malgorzata Buraczyk, Bialystok
Pro Familia Altera Sp. z o.o., Katowice
Ko-Med Centra Kliniczne Staszow, Staszów
Velocity Nova Sp. z o.o., Staszów
NBR Polska Tomasz Klodawski, Warsaw
Clinmedica Research sp. z o.o., Skierniewice
Manati Ctr For Clin Research, Manatí
Lead Sponsor
Novo Nordisk A/S
INDUSTRY